Fig. 3

Proposal for initiation of IFN-ß therapy of EV-positive patients. At time point of EV positive EMB the patients should be genotyped for CCR5 mutation. If CCR5del32 genotype is detected, no treatment with IFN-β is required, only clinical monitoring. If CCR5 wildtype genotype is determined IFN-β treatment is recommended for elimination of EV and resulting in improvement of the clinical course